TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. This is a free site for all.
Thank you.


Thursday, June 1, 2017

CLINICAL TRIAL OF SAFINAMIDE FOR PARKINSON'S DISEASE

May 31, 2017





Safinamide has both dopaminergic properties (highly selective and reversible inhibition of monoamine oxidase-B) and non-dopaminergic properties (selective sodium channel blockade and calcium channel modulation, with consequent inhibition of excessive glutamate release). It is added to the use of L-dopa or dopamine agonists. For more information go to Xadago : http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002396/h uman_med_001847.jsp&mid=WC0b01ac058001d124

The use of L-dopa is limited by wearing off and dyskinesias. The objective of this study was to investigate the efficacy and safety of safinamide in L-dopa treated patients who had motor fluctuations. If no tolerability issues arose by day 14, the starting dose, 50 mg, was increased to 100 mg. When taking safinamide, the mean change in daily on time without dyskinesia 2.80 hours. However, this was not much different from the effect that a placebo had. The most frequently reported adverse event was dyskinesia (14%], and as a severe event (2%). These results are consistent with previous studies in which the increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide.


Reference : JAMA Neurology [2017] 74 (2) : 216-224 (A.H.Schapira, S.H.Fox, R.A.Hauser, J.Jankovic, W.H.Jost, C.Kenney, J.Kulisevsky, R.Pahwa, W.Poewe, R.Anand)


Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/27942720


http://www.viartis.net/parkinsons.disease/news/170529.pdf mail@viartis.net
©2017 Viartis 

http://www.viartis.net/parkinsons.disease/news/170529.pdf

No comments:

Post a Comment